 |
|
Peptide discovered in scorpion venom may hold key to secretory diseases
February 15, 2008Researchers have discovered a peptide in scorpion venom that may hold the key to understanding and controlling cystic fibrosis and other secretory diseases.
In the December 28 issue of the Journal of Biological Chemistry, an international team of researchers describes how this novel peptide, called GaTx1, can control the movement of ions and water out of cells by interacting with a crucial chloride channel. This research was funded by the National Institutes of Health, National Science Foundation and Cystic Fibrosis Foundation.
"Peptide toxins from scorpions, snakes, snails and spiders paralyze prey by blocking nerve or muscle ion channels so the prey can't get away," explained Nael A. McCarty, an associate professor in the Georgia Institute of Technology's School of Biology. "Those toxins have been enormously useful for studying the potassium, calcium, and sodium channels that they interact with, but this is the first toxin discovered that potently binds to and selectively and reversibly inhibits a chloride channel of known molecular identity."
Chloride channels are crucial for secretion in many epithelial tissues, but little has been known about their structures and mechanisms. Researchers do know that chloride channels open to allow millions of chloride ions to travel through them and out of epithelial cells. This movement creates an osmotic gradient that allows water to flow.
For the more than 70,000 people worldwide affected by cystic fibrosis, a lack of water flow in airway cells results in abnormally thick, sticky mucus that commonly causes blockages that obstruct airways and glands. The lack of water flow stems from a problem in a chloride channel called the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
In individuals with cystic fibrosis, the CFTR protein is mutated, often with one or more amino acids deleted, and consequently misfolded. In the most common CFTR mutation leading to cystic fibrosis, the location of the deletion causes the chaperone proteins - which are responsible for quality assurance within cells - to bind to the misfolded proteins and discard them from the cell. Loss of CFTR proteins stops water from flowing into or out of the cells, thereby altering the conditions in the airway, leading to cystic fibrosis.
In other diseases, CFTR channels are overactive, which also causes problems. These include secretory diarrhea, a worldwide health concern causing thousands of deaths per year; diarrhea-predominant inflammatory bowel disease; and autosomal dominant polycystic kidney diseases, the fourth leading cause of end-stage renal disease in the United States.
With collaborators at the Hungarian Academy of Sciences, Emory University and the University of Calgary, the researchers used reversed-phase high-performance liquid chromatography (HPLC) to extract the novel GaTx1 peptide from the complex venom of the Giant Israeli Scorpion, Leiurus quinquestriatus hebraeus.
"We chose this technique because each different peptide has slightly different water solubility and hydrophobicity properties, allowing them to be separated," explained Julia Kubanek, an associate professor with joint appointments in the Georgia Tech School of Biology and School of Chemistry and Biochemistry.
Former Emory University graduate student Matthew Fuller and Georgia Tech graduate student Christopher Thompson collected individual peptides separated by the HPLC system and then applied each to chloride channels to see which peptide was responsible for the overall effects of the venom. They discovered a novel peptide that bound to the cytoplasmic side of the CFTR protein and weighed 3.7 kilodaltons - they called it GaTx1.
The researchers plan to use GaTx1 as a molecular probe to learn more about how chloride channels are structured and regulated. They also plan to study how this peptide can be useful in treating secretory diseases. For people with illnesses like secretory diarrhea, GaTx1 could be used to inhibit the channels from opening, in turn decreasing production of the watery diarrhea that often leads to death in patients suffering from cholera and other diarrheal diseases, said McCarty.
To treat patients with cystic fibrosis, GaTx1 could possibly be used to increase water production, by binding to the chaperone binding sites on the chloride channel. By blocking chaperones from binding, CFTR proteins would not be discarded and thus ions and water would flow from the cells to thin the mucus in the airway, according to McCarty.
"Even though the channels would be misfolded and probably only function at 50 percent capacity, chloride ions and water would still be transported through the cell," said McCarty. "This is better than the alternative of allowing the chaperones to discard all of the CFTR proteins."
McCarty has been studying CFTR for his entire research career and as he moves to a new position as associate professor in pediatrics and senior cystic fibrosis scientist at Emory University, he will continue this work in collaboration with researchers at Georgia Tech.
"GaTx1 has the potential to be used as a drug to help patients with cystic fibrosis and these other secretory diseases," added McCarty. "My new role at Emory will allow me to conduct pre-clinical studies to explore experimental drug treatment options based on this toxin."
Georgia Institute of Technology Research News
Chloride channels are crucial for secretion in many epithelial tissues, but little has been known about their structures and mechanisms. Researchers do know that chloride channels open to allow millions of chloride ions to travel through them and out of epithelial cells. This movement creates an osmotic gradient that allows water to flow.
For the more than 70,000 people worldwide affected by cystic fibrosis, a lack of water flow in airway cells results in abnormally thick, sticky mucus that commonly causes blockages that obstruct airways and glands. The lack of water flow stems from a problem in a chloride channel called the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
In individuals with cystic fibrosis, the CFTR protein is mutated, often with one or more amino acids deleted, and consequently misfolded. In the most common CFTR mutation leading to cystic fibrosis, the location of the deletion causes the chaperone proteins - which are responsible for quality assurance within cells - to bind to the misfolded proteins and discard them from the cell. Loss of CFTR proteins stops water from flowing into or out of the cells, thereby altering the conditions in the airway, leading to cystic fibrosis.
In other diseases, CFTR channels are overactive, which also causes problems. These include secretory diarrhea, a worldwide health concern causing thousands of deaths per year; diarrhea-predominant inflammatory bowel disease; and autosomal dominant polycystic kidney diseases, the fourth leading cause of end-stage renal disease in the United States.
With collaborators at the Hungarian Academy of Sciences, Emory University and the University of Calgary, the researchers used reversed-phase high-performance liquid chromatography (HPLC) to extract the novel GaTx1 peptide from the complex venom of the Giant Israeli Scorpion, Leiurus quinquestriatus hebraeus.
"We chose this technique because each different peptide has slightly different water solubility and hydrophobicity properties, allowing them to be separated," explained Julia Kubanek, an associate professor with joint appointments in the Georgia Tech School of Biology and School of Chemistry and Biochemistry.
Former Emory University graduate student Matthew Fuller and Georgia Tech graduate student Christopher Thompson collected individual peptides separated by the HPLC system and then applied each to chloride channels to see which peptide was responsible for the overall effects of the venom. They discovered a novel peptide that bound to the cytoplasmic side of the CFTR protein and weighed 3.7 kilodaltons - they called it GaTx1.
The researchers plan to use GaTx1 as a molecular probe to learn more about how chloride channels are structured and regulated. They also plan to study how this peptide can be useful in treating secretory diseases. For people with illnesses like secretory diarrhea, GaTx1 could be used to inhibit the channels from opening, in turn decreasing production of the watery diarrhea that often leads to death in patients suffering from cholera and other diarrheal diseases, said McCarty.
To treat patients with cystic fibrosis, GaTx1 could possibly be used to increase water production, by binding to the chaperone binding sites on the chloride channel. By blocking chaperones from binding, CFTR proteins would not be discarded and thus ions and water would flow from the cells to thin the mucus in the airway, according to McCarty.
"Even though the channels would be misfolded and probably only function at 50 percent capacity, chloride ions and water would still be transported through the cell," said McCarty. "This is better than the alternative of allowing the chaperones to discard all of the CFTR proteins."
McCarty has been studying CFTR for his entire research career and as he moves to a new position as associate professor in pediatrics and senior cystic fibrosis scientist at Emory University, he will continue this work in collaboration with researchers at Georgia Tech.
"GaTx1 has the potential to be used as a drug to help patients with cystic fibrosis and these other secretory diseases," added McCarty. "My new role at Emory will allow me to conduct pre-clinical studies to explore experimental drug treatment options based on this toxin."
Georgia Institute of Technology Research News
Cystic Fibrosis Current Events and Cystic Fibrosis News RSSChildren with cystic fibrosis not well covered by guidelines for vitamin D needs
Existing recommendations for treating vitamin D deficiency in children with cystic fibrosis (CF) are too low to cover the serious need, leaving most at high risk for bone loss and rickets, according to researchers at Johns Hopkins Children's Center.
New approach to treating cystic fibrosis lung infection shows promise
Researchers at the University of Calgary have found a new method of fighting severe lung infections in people with cystic fibrosis (CF). These findings are published in Proceedings of the National Academy of Science USA, this week.
Protein opens hope of treatment for cystic fibrosis patients
Scientists have finally identified a direct role for the missing protein that leaves cystic fibrosis patients open to attack from lung-damaging bacteria, the main reason most of them die before their 35th birthday, scientists heard today (Thursday 11 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.
Rattlesnake-type poisons used by superbug bacteria to beat our defenses
Colonies of hospital superbugs can make poisons similar to those found in rattlesnake venom to attack our bodies' natural defences, scientists heard today (Monday 8 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.
Clearing the airways in cystic fibrosis
By manipulating the machinery used by our cells for quality control, researchers from the University of Pittsburgh have found a way to restore the function of cystic fibrosis (CF) airway cells.
PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
New phase 2 data published today in The Lancet show that the investigational oral drug PTC124 demonstrates activity in nonsense-mutation cystic fibrosis (CF). The data show that treatment with PTC124 results in statistically significant improvements in the chloride channel function of patients with nonsense-mutation CF. The study was conducted at the Hadassah Hebrew University Hospital in Jerusalem, Israel and sponsored by PTC Therapeutics (PTC).
Breaking the 'mucus barrier' with a new drug delivery system
Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus - regarded by many as nearly impenetrable - and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.
NIH scientists find a novel mechanism that controls the development of autoimmunity
Scientists at the National Institutes of Health (NIH) have found a mechanism in the immune systems of mice that can lead to the development of autoimmune disease when turned off.
Researchers discover cell's 'quality control' mechanism
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
Most generalists reluctant to provide primary care for young adults with chronic illness
The majority of general internists and pediatricians in the United States are not comfortable serving as primary care providers for young adults with complex chronic illnesses that originate during childhood, according to findings from a new national survey.
More Cystic Fibrosis Current Events and Cystic Fibrosis News Articles
 | Cystic Fibrosis: Everything You Need To Know (Your Personal Health) by Wayne Kepron Cystic fibrosis afflicts approximately 30,000 Americans. The average age of survival has been steadily increasing, but not quickly enough: a child born with cystic fibrosis today can only expect to live 35 to 40 years. In this valuable new addition to the Your Personal Health series, Dr. Wayne Kepron offers a comprehensive look at the disease that afflicts so many young people. Topics... |
 | Cadberry's Letters by Jennifer Racek Cadberry's mom is very forgetful. Every time they visit his doctor together she talks about C & F. She never remembers the other letters. When Cadberry draws a set of letters to help his mother remember them all, he discovers what C & F really mean and how those two tiny letters affect so much of his life. Developed for pre-school-age children, Cadberry's Letters uses simple, easy-to-follow... |
 | With Every Breath: stories by and about people living with cystic fibrosis Over 30,000 people in the US have cystic fibrosis, a life-threatening genetic disease that affects the lungs and digestive system. Physically, fighting it is a very perilous struggle. Emotionally, coping can oftentimes be even harder. With Every Breath consists of stories by and about people living with cystic fibrosis. Created to motivate, inspire, and generate positivity for those living... |
 | David's Promise: A Young Man's Struggle with Cystic Fibrosis by Kathy Sykes What would it be like to navigate this life under the shadow of a deadly disease? How would you cope, both physically and psychologically? Approximately 30,000 people in our country live with the devastating illness, cystic fibrosis, and one in twenty Caucasians are carriers of its gene. Many among us are affected by CF, but few really know much about it. David's Promise delivers an in-depth... |
 | Cystic Fibrosis (Facts) by Ann Harris, Anne Thomson Cystic Fibrosis: The Facts provides a much needed simple and understandable source book about this disease. It is aimed at those living with Cystic Fibrosis (CF), either themselves or members of their families or their friends. The book explains clearly what is happening to the body in CF, what causes it and what treatment options are available for the different aspects of the disease. There... |
 | The Power of Two: A Twin Triumph over Cystic Fibrosis by Isabel Stenzel Byrnes; Anabel Stenzel The tragedy of cystic fibrosis has been touchingly recounted before, but this is the first book to portray the symbiotic relationship between twins who share this life-threatening disease through adulthood. Isabel Stenzel Byrnes and Anabel Stenzel tell of their struggle to pursue normal lives while grappling with the realization that they might die young. Their story reflects the physical and... |
 | Cystic Fibrosis: A Guide for Patient and Family Written by Dr. David Orenstein, director of one of the nation's leading CF centers, this one-of-a-kind guide offers clear explanations and real-world advice on cystic fibrosis and its management. Here you'll find practical and reassuring information on day-to-day concerns--school, travel, exercise, nutrition, medication--as well as on physiological effects, long-term issues, and prospects for a... |
 | ALEX, THE LIFE OF A CHILD - The unforgettable story of a courageous little girl's battle for life against Cystic Fibrosis by Frank Deford |
 | Diseases and Disorders - Cystic Fibrosis (Diseases and Disorders) by Melissa Abramovitz Cystic fibrosis is an inherited disorder of the lungs and digestive system, and is the most common fatal hereditary disease in the U.S. While there is no cure for cystic fibrosis, many recent developments in medicine and gene therapy have made it easier for people to live their lives with this debilitating disease.... |
 | Living on Borrowed Time: Life with Cystic Fibrosis by Debbie Pitts |
| © 2008 BrightSurf.com |